Author

Fitsum Ghebretinsea

Observed names: F. Ghebretinsea, Ghebretinsea, Fitsum

Institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

Observed institutions: University of Oxford, Cancer Research UK Clinical Trials Unit, University of Birmingham

ORCID: 0000-0002-4122-4102

Observed ORCID: 0000-0002-4122-4102

OpenAlex ID: A5005875349

Extended follow-up of a short total diet replacement programme: results of the Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET) randomised controlled trial at 3 years

2021 · Nerys M. Astbury, Rhiannon M. Edwards, et al. · International Journal of Obesity · 13

1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)

2025 · H.M. Mehanna, P. Gaunt, et al. · Annals of Oncology · 5

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

2025 · Graham McIlroy, Charlotte Gaskell, et al. · BMC Cancer · 5

Testing the short‐term effectiveness of primary care referral to online weight loss programmes: A randomised controlled trial

2021 · Michaela Noreik, Claire D. Madigan, et al. · Clinical Obesity · 5

Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I R IVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).

2025 · Hans Merks, Fitsum Ghebretinsea, et al. · Journal of Clinical Oncology · 1

Works count: 14

Citation count: 29

H-index: 4

I10-index: 1